Arcadia Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2013
Net Income	-7.02	-13.98	-15.38	-14.66	-4.66	-28.81	Upgrade
Depreciation & Amortization	0.96	0.98	1.36	2.32	1.71	0.9	Upgrade
Share-Based Compensation	0.64	0.72	1.11	1.54	2.04	2.29	Upgrade
Other Operating Activities	-9.62	-3.01	-1.07	-15.07	-29.32	8.42	Upgrade
Operating Cash Flow	-15.04	-15.29	-13.98	-25.87	-30.22	-17.2	Upgrade
Capital Expenditures	0.08	0.11	0.85	-0.99	-2.33	-1.46	Upgrade
Acquisitions	0.28	0.57	0.57	-4.25	2.65	0	Upgrade
Change in Investments	-5.02	-5.02	0	21.85	16.96	-6.91	Upgrade
Investing Cash Flow	-4.66	-4.34	1.42	16.61	17.28	-8.37	Upgrade
Share Issuance / Repurchase	0.01	6.01	5.01	25.17	16.51	22.77	Upgrade
Debt Issued / Paid	0	0	0	-2.15	3.07	-0.01	Upgrade
Other Financing Activities	-	-0.5	-0.49	-1.12	0.98	-0.78	Upgrade
Financing Cash Flow	0.01	5.51	4.52	21.9	20.56	21.99	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	Upgrade
Net Cash Flow	-19.68	-14.13	-8.04	12.64	7.63	-3.58	Upgrade
Free Cash Flow	-14.95	-15.18	-13.13	-26.86	-32.55	-18.66	Upgrade
Free Cash Flow Margin	-276.36%	-284.88%	-176.99%	-396.11%	-405.09%	-1596.15%	Upgrade
Free Cash Flow Per Share	-10.98	-12.28	-21.90	-50.48	-130.72	-117.30	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).